Tafamidis ATTR Cm denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tafamidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Tafamidis-Attr-Cm as Experimental — and Why This Classification Is Not Supportable

An "experimental or investigational" denial for tafamidis in ATTR cardiomyopathy (ATTR-CM) is factually incorrect as applied to the FDA-approved indication. Tafamidis received full FDA approval for ATTR-CM after completing a phase 3 randomized controlled trial and demonstrating substantial evidence of clinical benefit. An experimental denial in this context almost always reflects a plan's clinical policy that has not been updated since the approval, a miscoded indication on the claim or PA request, or an internal coverage policy that predates or incorrectly interprets the FDA's determination.

This category of denial has a high overturn rate on external review because IROs apply the legal standard of whether a treatment has received FDA approval for the relevant indication — and tafamidis has.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): Request the specific clinical criteria UHC used to classify tafamidis as experimental. Under ERISA, you are entitled to the full administrative record including the clinical review rationale.
• External review: This denial type is particularly well-suited for external review because an IRO will independently assess whether the treatment is experimental under accepted clinical standards — not UHC's internal policy. Federal law provides approximately four months to request external review after the internal appeal is exhausted. Expedited review is available.

## Documentation to Gather

1. FDA approval documentation — print the current approval letter and label from drugs.fda.gov. Confirm the indication matches the patient's diagnosis. This is your strongest single document. 2. Diagnosis confirmation — cardiology records confirming ATTR-CM (wild-type or hereditary), including the diagnostic workup. 3. Applicable guideline endorsement — your prescriber should reference that the relevant ACC/AHA or applicable cardiology guideline organization recognizes tafamidis as a treatment option for ATTR-CM. 4. Prescriber medical-necessity letter — specifically rebut the "experimental" classification by citing the FDA approval date and the fact that the treatment is standard of care per current cardiology guidelines. 5. UHC's clinical policy — request UHC's current coverage policy for tafamidis/ATTR-CM and identify where, if anywhere, it characterizes the drug as experimental. If the policy is out of date, flag that explicitly.

## Criteria-Mapping Structure

| UHC Experimental Criterion | Your Rebuttal | |---|---| | FDA approval status | Attach FDA label; approval date confirmed | | Clinical trial evidence | FDA approval reflects completed pivotal trial; IRO applies FDA standard | | Guideline recognition | Prescriber letter cites current ACC/AHA position | | Indication match | Patient diagnosis matches FDA-approved indication (chart + label attached) |

Do not accept this denial without appealing. Experimental denials for FDA-approved drugs have very high external-review overturn rates.